Abstract
Since 2003, highly pathogenic H5N1 influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. At present, there are only three licensed anti-Influenza drugs namely Relenza (Zanamivir - ZMV), Tamiflu (Oseltamivir - OTV) and Amantadine/Rimantadine. The latter targets the M2 ion channel whereas the other compounds target neuraminidase (NA) and were designed through structure-based enzyme inhibitor programmes. Some structural knowledge of the Influenza neuraminidase is now known, due to remarkable advances in crystallographic techniques. The structure of H5N1 NA is particularly attractive because it offers new opportunities for drug design. Besides a profound impact that structural biology has had on understanding the Influenza virus and the rational design of antivirals, computational methods are now a viable partner to experiment in designing NA inhibitors. We herein discuss the development of current neuraminidase inhibitors, the emergence of resistance to them and recent research progress towards the development of new inhibitors.
Keywords: Avian H5N1 influenza virus, neuraminidase, Oseltamivir, Zanamivir, drug design
Current Drug Targets
Title: Advances in the Structure-Based Design of the Influenza A Neuraminidase Inhibitors
Volume: 11 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Avian H5N1 influenza virus, neuraminidase, Oseltamivir, Zanamivir, drug design
Abstract: Since 2003, highly pathogenic H5N1 influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. At present, there are only three licensed anti-Influenza drugs namely Relenza (Zanamivir - ZMV), Tamiflu (Oseltamivir - OTV) and Amantadine/Rimantadine. The latter targets the M2 ion channel whereas the other compounds target neuraminidase (NA) and were designed through structure-based enzyme inhibitor programmes. Some structural knowledge of the Influenza neuraminidase is now known, due to remarkable advances in crystallographic techniques. The structure of H5N1 NA is particularly attractive because it offers new opportunities for drug design. Besides a profound impact that structural biology has had on understanding the Influenza virus and the rational design of antivirals, computational methods are now a viable partner to experiment in designing NA inhibitors. We herein discuss the development of current neuraminidase inhibitors, the emergence of resistance to them and recent research progress towards the development of new inhibitors.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in the Structure-Based Design of the Influenza A Neuraminidase Inhibitors, Current Drug Targets 2010; 11 (3) . https://dx.doi.org/10.2174/138945010790711932
DOI https://dx.doi.org/10.2174/138945010790711932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Propylene Carbonate as a Solvent in the Eco-Friendly Synthesis of Highly Substituted Imidazoles Through the Radziszewski Reaction
Current Organic Synthesis The Undiscovered Potential of Essential Oils for Treating SARS-CoV-2 (COVID-19)
Current Pharmaceutical Design Partially Ordered Sets: Ranking and Prediction of Substances Properties
Current Computer-Aided Drug Design Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Triggers for Acceptance of COVID-19 Vaccination: A Community- Based Study
Recent Advances in Anti-Infective Drug Discovery Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy
Current Medicinal Chemistry α-Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors
Mini-Reviews in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents
Medicinal Chemistry Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Chronological Order Based Wrapper Technique for Drug-Target Interaction Prediction (CO-WT DTI)
Current Bioinformatics The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) <i>In silico</i> Screening of Phytoconstituents with Antiviral Activities Against SARS-COV-2 Main Protease, Nsp12 Polymerase, and Nsp13 Helicase Proteins
Letters in Drug Design & Discovery Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Current Topics in Medicinal Chemistry SARS-CoV-2: Possible Factors Contributing to Serious Consequences of COVID-19?
New Emirates Medical Journal Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19
Current Neuropharmacology Current Progress in Antifibroitcs
Current Medicinal Chemistry Synthesis and In Silico Molecular Docking Studies on Substituted Piperic Acid Derivatives as Inhibitors of Bacterial DNA Gyrase
Current Computer-Aided Drug Design Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets